Edwards Lifesciences VP Donald Bobo to Retire in Mid‑2027

What Happened

• Edwards Lifesciences (EW) filed an 8‑K on Aug. 28, 2026, disclosing that Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, has notified the Board he will retire from the company by mid‑year 2027.
• The company will begin a successor selection process promptly, expects a transition of duties during 2027, and Mr. Bobo is expected to remain as a consultant through the end of 2027.

Key Details

• Filing date: August 28, 2026 (Form 8‑K, Item 5.02).
• Officer: Donald E. Bobo, Jr., Corporate VP, Strategy and Corporate Development.
• Retirement effective: by mid‑2027; consulting role through December 31, 2027 (expected).
• Company contact/signature on the filing: Theodora Mistras, Chief Financial Officer.

Why It Matters

• This is an executive succession event in Edwards’ strategy and corporate development leadership, which could affect how the company evaluates and executes acquisitions, partnerships, and strategic initiatives.
• The firm has initiated a search and plans a transition period plus consulting support from Mr. Bobo, which may help preserve continuity while a successor is identified.